Novel drug shows promise against acute myeloid leukemia

April 11, 2018, Albert Einstein College of Medicine
Bone marrow aspirate showing acute myeloid leukemia. Several blasts have Auer rods. Credit: Wikipedia

In a study published online today in Science Translational Medicine, Albert Einstein College of Medicine researchers report that an experimental peptide (small protein) drug shows promise against the often-lethal cancer acute myeloid leukemia (AML) and describe how the drug works at the molecular level. The findings have led to a Phase I/II clinical trial for patients with advanced AML and advanced myelodysplastic syndrome (MDS), now underway at Montefiore Health System.

In preclinical studies, the experimental drug—ALRN-6924—tripled the median survival rate in an animal model of human AML (mice transplanted with human leukemia cells) from 50 to about 150 days.

"This is a very striking response," said study leader Ulrich Steidl, M.D., Ph.D., professor of cell biology and of medicine and the Diane and Arthur B. Belfer Faculty Scholar in Cancer Research at Einstein and associate chair for translational research in oncology at Montefiore. "Most experimental drugs for leukemia achieve an increase in survival of only a few days in these preclinical models. Even more importantly, ALRN-6924 effectively cured about 40 percent of the treated mice, meaning they were disease free more than one year after treatment—essentially a lifetime for a mouse."

AML is caused by damage to the DNA of blood-forming in the bone marrow, resulting in abnormal white , , or platelets. About 21,000 people in the U.S. were diagnosed with AML in 2017. Only 27 percent of people diagnosed with AML survive for five or more years, an outcome that has not significantly improved in the past half-century.

In this video of cancer cells, each flickering white spot means that the stapled peptide drug has turned on previously-inactivated p53 tumor suppressor protein. Credit: Adrien Senecal, Robert H. Singer, and Robert A. Coleman (Albert Einstein College of Medicine)

ALRN-6924 was developed by Aileron Therapeutics Inc. to target p53, a protein that suppresses tumors but is inactivated in many forms of cancer including AML. The drug was designed to inhibit two naturally occurring proteins, MDMX and MDM2, whose overexpression inactivates p53, allowing cancer cells to multiply unchecked. Aileron turned to Dr. Steidl, an AML expert, to test the drug's effectiveness in preclinical models of AML and to find out more about its mechanism of action.

Dr. Steidl and his colleagues confirmed that ALRN-6924 targets both MDMX and MDM2, blocking their interaction with p53 in AML cells. That effect was seen in both more mature AML cells and the immature stem cells that produce them. "This is important," said Dr. Steidl, "because AML is driven by stem cells—and if you don't target stem cells, the disease will come back very quickly."

Those same molecular changes were observed in blood cells of an AML patient who was given the drug on a compassionate-use basis. "This test was not designed to assess the efficacy of the in humans—that has to be done in a proper clinical trial," said Dr. Steidl. "Our goal was to determine whether it can hit the desired target in human in a clinical setting, which it did in this individual."

ALRN-6924 is a so-called stapled alpha-helical peptide, a promising new class of drugs whose helical structure is stabilized using hydrocarbon "staples." The stapling prevents the peptides from being degraded by enzymes before reaching their intended target, a fate that often befalls conventional peptide drugs. ALRN-6924 is the first stapled peptide therapeutic to be tested in patients.

The study is titled, "Dual Inhibition of MDMX and MDM2 as a Therapeutic Strategy in Leukemia."

Explore further: Data: ATSP-7041 as first-in-class p53 pathway re-activator for solid, hematologic cancers

More information: L.A. Carvajal el al., "Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia," Science Translational Medicine (2018). stm.sciencemag.org/lookup/doi/ … scitranslmed.aao3003

Related Stories

Data: ATSP-7041 as first-in-class p53 pathway re-activator for solid, hematologic cancers

August 15, 2013
Aileron Therapeutics, Inc., a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, announced today the publication of preclinical ...

Gene discovery could improve treatment for acute myeloid leukemia

August 13, 2012
Scientists at Albert Einstein College of Medicine of Yeshiva University have made a discovery involving mice and humans that could mean that people with acute myeloid leukemia (AML), a rare and usually fatal cancer, are a ...

Chemical stem cell signature predicts treatment response for acute myeloid leukemia

February 3, 2014
Researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have found a chemical "signature" in blood-forming stem cells that predicts whether patients with acute myeloid leukemia ...

Myelodysplastic syndromes (MDS) linked to abnormal stem cells

July 2, 2012
Researchers at Albert Einstein College of Medicine of Yeshiva University have found that abnormal bone marrow stem cells drive the development of myelodysplastic syndromes (MDS), serious blood diseases that are common among ...

Blocking key pathways is a way to defeat cancer stem cells

October 25, 2017
Scientists from the RIKEN Center for Integrative Medical Sciences in Japan and international collaborators have found that in humanized mice, a cocktail of drugs blocking certain key pathways is effective in eliminating acute ...

Prostaglandin E1 inhibits leukemia stem cells

September 25, 2017
Two drugs, already approved for safe use in people, may be able to improve therapy for chronic myeloid leukemia (CML), a blood cancer that affects myeloid cells, according to results from a University of Iowa study in mice.

Recommended for you

Magnetized wire could be used to detect cancer in people, scientists report

July 16, 2018
A magnetic wire used to snag scarce and hard-to-capture tumor cells could prove to be a swift and effective tactic for early cancer detection, according to a study by researchers at the Stanford University School of Medicine.

Researchers suggest new treatment for rare inherited cancers

July 16, 2018
Studying two rare inherited cancer syndromes, Yale Cancer Center (YCC) scientists have found the cancers are driven by a breakdown in how cells repair their DNA. The discovery, published today in Nature Genetics, suggests ...

Researchers map 'family trees' of acute myeloid leukemia

July 16, 2018
For the first time, a team of international researchers has mapped the family trees of cancer cells in acute myeloid leukaemia (AML) to understand how this blood cancer responds to a new drug, enasidenib. The work also explains ...

Scientists sharpen the edges of cancer chemotherapy with CRISPR

July 13, 2018
Tackling unsolved problems is a cornerstone of scientific research, propelled by the power and promise of new technologies. Indeed, one of the shiniest tools in the biomedical toolkit these days is the genome editing system ...

Products of omega-3 fatty acid metabolism may have anticancer effects, study shows

July 13, 2018
A class of molecules formed when the body metabolizes omega-3 fatty acids could inhibit cancer's growth and spread, University of Illinois researchers report in a new study in mice. The molecules, called endocannabinoids, ...

Looking at the urine and blood may be best in diagnosing myeloma

July 13, 2018
When it comes to diagnosing a condition in which the plasma cells that normally make antibodies to protect us instead become cancerous, it may be better to look at the urine as well as the serum of our blood for answers, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.